Why the study?
Does the use of age- and gender-specific 99th percentile cut-offs for high-sensitivity cardiac troponin improve the diagnosis of acute myocardial infarction compared to solitary cut-offs?
Does the use of age- and gender-specific 99th percentile cut-offs for high-sensitivity cardiac troponin improve the diagnosis of acute myocardial infarction compared to solitary cut-offs?
Answers are grounded in this paper and cite their sources.
Current evidence is ambiguous regarding the routine use of age- and gender-specific high-sensitivity troponin cut-offs for diagnosing acute myocardial infarction, suggesting solitary cut-offs remain standard practice.
According to the universal definition, a diagnosis of acute myocardial infarction (AMI) can be made in the presence of a kinetic change of cardiac troponin (cTn) with at least one value above the 99th percentile of a healthy population together with clinical signs of myocardial ischemia. Thus, differences in 99th percentile cut-off values may have important diagnostic and therapeutic consequences for the correct AMI diagnosis. Following the introduction of high-sensitivity (hs) cTn assays with the ability to detect cTn in virtually every healthy individual, almost all available hs Tn assays suggest to use solitary 99th percentile cut-offs. However, several findings have questioned the use of a solitary cut-off for AMI diagnosis, as apparent age- and gender-dependent differences were found concerning the 99th percentile cut-off value. Moreover, there is an increasing number of studies which suggest a relevant diagnostic and prognostic benefit, when age- or gender-specific cut-offs values are used in comparison to general cut-offs. In contrast, other studies observed only a small impact on diagnostic reclassification and risk stratification. Given these ambiguous findings, there is currently no clear evidence for the use of age- and/or gender-dependent 99th percentiles. This review gives an overview of the rationale for gender- and age-dependent differences in cTn biomarker findings and discusses the implementation of these findings into clinical practice.
No takes yet. Share an insight, caveat, or question.
Mueller‐Hennessen et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: